<SEC-DOCUMENT>0001558370-24-002189.txt : 20240229
<SEC-HEADER>0001558370-24-002189.hdr.sgml : 20240229
<ACCEPTANCE-DATETIME>20240229161533
ACCESSION NUMBER:		0001558370-24-002189
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20240229
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240229
DATE AS OF CHANGE:		20240229

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PTC THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001070081
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				043416587
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35969
		FILM NUMBER:		24703843

	BUSINESS ADDRESS:	
		STREET 1:		100 CORPORATE COURT
		CITY:			SOUTH PLAINFIELD
		STATE:			NJ
		ZIP:			07080-2449
		BUSINESS PHONE:		9082227000

	MAIL ADDRESS:	
		STREET 1:		100 CORPORATE COURT
		CITY:			SOUTH PLAINFIELD
		STATE:			NJ
		ZIP:			07080-2449

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PTC THERAPEUTICS INC
		DATE OF NAME CHANGE:	19980909
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tmb-20240229x8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ptct="http://www.ptcbio.com/20240229" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance"><head><meta http-equiv="content-type" content="text/html"/><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_2_29_2024_To_2_29_2024_g9hADND3XUK0dRK0JVWoBA" name="dei:EntityCentralIndexKey" id="Tc_cIFpiC3XdUWBvdZnJ-vSNQ_2_1">0001070081</ix:nonNumeric><ix:nonNumeric contextRef="Duration_2_29_2024_To_2_29_2024_g9hADND3XUK0dRK0JVWoBA" name="dei:AmendmentFlag" id="Tc_a1EH3V3txkulBPp7HTVVQQ_3_1">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="tmb-20240229.xsd" xlink:type="simple"/></ix:references><ix:resources><xbrli:context id="Duration_2_29_2024_To_2_29_2024_g9hADND3XUK0dRK0JVWoBA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-29</xbrli:startDate><xbrli:endDate>2024-02-29</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:2pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_3fc39a1a_887a_483a_8c79_81c09bc11603"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:17pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:17pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">WASHINGTON, D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:17pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_2_29_2024_To_2_29_2024_g9hADND3XUK0dRK0JVWoBA" name="dei:DocumentType" id="Narr_PR4ssrHA8kSo6vj8KUfkQQ"><b style="font-weight:bold;">8-K</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">CURRENT REPORT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Pursuant to Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;white-space:pre-wrap;">Date of Report (Date of earliest event reported):  </span><ix:nonNumeric contextRef="Duration_2_29_2024_To_2_29_2024_g9hADND3XUK0dRK0JVWoBA" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="Narr_7qk3w9mIQ06n6k0heq9CBA"><b style="font-size:9pt;font-weight:bold;">February 29, 2024</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:17pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_29_2024_To_2_29_2024_g9hADND3XUK0dRK0JVWoBA" name="dei:EntityRegistrantName" id="Narr_SH9MVZt7Fkib9NX50J_ceg"><b style="font-weight:bold;">PTC THERAPEUTICS, INC.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Exact Name of Company as Specified in Charter)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_55447ebd_8ac3_48f2_9214_a2803b87ebd3"></a><a id="Tc_i2v1ccJSZEuYHLcq05yfVQ_2_0"></a><a id="Tc_OumKbxUb70ip7xYE79iKrA_2_2"></a><a id="Tc_Uxx_vMU-7Umqwtntor2WPQ_2_4"></a><a id="Tc_0hGG_IkHpkGV-wfBDXhAeQ_3_0"></a><a id="Tc_WFSdJZK_u02XdhS2C3jJ_A_3_2"></a><a id="Tc_fJB3QmPgZkOhQ-PktCmONA_3_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:31.75%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:31.76%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:31.76%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:31.75%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_29_2024_To_2_29_2024_g9hADND3XUK0dRK0JVWoBA" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="Tc_txef5zQOVEKDFL3URT-GZw_1_0"><b style="font-size:9pt;font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:31.76%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_29_2024_To_2_29_2024_g9hADND3XUK0dRK0JVWoBA" name="dei:EntityFileNumber" id="Tc_Ll3fVuA9PkehTmBdDWRX4Q_1_2"><b style="font-size:9pt;font-weight:bold;">001-35969</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:31.76%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_29_2024_To_2_29_2024_g9hADND3XUK0dRK0JVWoBA" name="dei:EntityTaxIdentificationNumber" id="Tc_zvGLVyO7PUiVlqD_HaSPKw_1_4"><b style="font-size:9pt;font-weight:bold;">04-3416587</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:31.75%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(State or Other Jurisdiction</p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.76%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Commission</p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.76%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(IRS Employer</p></td></tr><tr><td style="vertical-align:bottom;width:31.75%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">of Incorporation)</p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.76%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">File Number)</p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.76%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">Identification No.)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><a id="_c0dd52bc_18a5_4ddb_b41a_c697e874a0ff"></a><a id="Tc_7Xio0PHNOU-oloNa5t9GbQ_2_0"></a><a id="Tc_rl--4VBGkESDNWRmZwtShA_3_0"></a><a id="Tc_gE3VuYjn2UiFjVdJbmGuew_3_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:48.53%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_29_2024_To_2_29_2024_g9hADND3XUK0dRK0JVWoBA" name="dei:EntityAddressAddressLine1" id="Tc_XBUCC2Rsn0CvyetDFZd8-Q_1_0"><b style="font-size:9pt;font-weight:bold;">100 Corporate Court</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:48.53%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_29_2024_To_2_29_2024_g9hADND3XUK0dRK0JVWoBA" name="dei:EntityAddressCityOrTown" id="Narr_P9kt5sUGHUSfZO5L7oMVJg"><b style="font-size:9pt;font-weight:bold;">South Plainfield</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_2_29_2024_To_2_29_2024_g9hADND3XUK0dRK0JVWoBA" name="dei:EntityAddressStateOrProvince" id="Narr_7wIQvYTIMECUTbHTw5aKeg"><b style="font-size:9pt;font-weight:bold;">NJ</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.53%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_29_2024_To_2_29_2024_g9hADND3XUK0dRK0JVWoBA" name="dei:EntityAddressPostalZipCode" id="Tc_HN8l5sA2sE6Ef31NTQ7Bww_2_2"><b style="font-size:9pt;font-weight:bold;">07080</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Address of Principal Executive Offices)</p></td><td style="vertical-align:bottom;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.53%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Zip Code)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;">Registrant&#8217;s telephone number, including area code: </span><b style="font-size:9pt;font-weight:bold;">(</b><ix:nonNumeric contextRef="Duration_2_29_2024_To_2_29_2024_g9hADND3XUK0dRK0JVWoBA" name="dei:CityAreaCode" id="Narr_2_FLiF99GE-V6F9fs5NnSA"><b style="font-size:9pt;font-weight:bold;">908</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_2_29_2024_To_2_29_2024_g9hADND3XUK0dRK0JVWoBA" name="dei:LocalPhoneNumber" id="Narr_d5M2yavbJU2nHicoAuigrw"><b style="font-size:9pt;font-weight:bold;">222-7000</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Not applicable</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Former Name or Former Address, if Changed Since Last Report)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-indent:36pt;margin:0pt;">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<i style="font-style:italic;">see</i> General Instruction A.2. below):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:21.6pt;"><ix:nonNumeric contextRef="Duration_2_29_2024_To_2_29_2024_g9hADND3XUK0dRK0JVWoBA" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="Narr_n1jrmQcbtkujW2hTC6t_Ng"><span style="font-family:'Segoe UI Symbol';font-size:9pt;font-style:normal;font-weight:normal;">&#9744;</span></ix:nonNumeric></span><span style="font-size:9pt;">Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:21.6pt;"><ix:nonNumeric contextRef="Duration_2_29_2024_To_2_29_2024_g9hADND3XUK0dRK0JVWoBA" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="Narr_WevhHgZStk6AsHMTQO0wsQ"><span style="font-family:'Segoe UI Symbol';font-size:9pt;font-style:normal;font-weight:normal;">&#9744;</span></ix:nonNumeric></span><span style="font-size:9pt;">Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:21.6pt;"><ix:nonNumeric contextRef="Duration_2_29_2024_To_2_29_2024_g9hADND3XUK0dRK0JVWoBA" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="Narr_a9jxHFEf9ESE79h9zSnYJw"><span style="font-family:'Segoe UI Symbol';font-size:9pt;font-style:normal;font-weight:normal;">&#9744;</span></ix:nonNumeric></span><span style="font-size:9pt;">Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:21.6pt;"><ix:nonNumeric contextRef="Duration_2_29_2024_To_2_29_2024_g9hADND3XUK0dRK0JVWoBA" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="Narr_JAmeC3OyU0ipisgtoPR_dQ"><span style="font-family:'Segoe UI Symbol';font-size:9pt;font-style:normal;font-weight:normal;">&#9744;</span></ix:nonNumeric></span><span style="font-size:9pt;">Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c))</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_78f9e492_9551_4dcc_bd52_e93e8cab4c26"></a><a id="Tc_S0j_RKPBX0SdWcTKcedoig_1_0"></a><a id="Tc_A0DfkH01bUWKQQAAEZ7ouQ_1_2"></a><a id="Tc_jKAhq3SICEiLrtTqgHKbHA_1_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:37.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:19.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:37.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:37.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title of each class</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:19.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Trading Symbol(s)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:37.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name of each exchange on which registered</b></p></td></tr><tr><td style="vertical-align:bottom;width:37.99%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_29_2024_To_2_29_2024_g9hADND3XUK0dRK0JVWoBA" name="dei:Security12bTitle" id="Tc_Mu3NUdZGdk6ApAm2l-gaWQ_2_0"><span style="font-size:9pt;">Common Stock, $0.001 par value per share</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:19.99%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_29_2024_To_2_29_2024_g9hADND3XUK0dRK0JVWoBA" name="dei:TradingSymbol" id="Tc_jgEwRN5KMkGCJXn3WT6QYw_2_2"><span style="font-size:9pt;">PTCT</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:37.84%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_29_2024_To_2_29_2024_g9hADND3XUK0dRK0JVWoBA" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="Tc_M4HEJyC9aEuATAHy5Os8pw_2_4"><span style="font-size:9pt;">Nasdaq Global Select Market</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule&#160;405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&#160;12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;">Emerging growth company </span><ix:nonNumeric contextRef="Duration_2_29_2024_To_2_29_2024_g9hADND3XUK0dRK0JVWoBA" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="Narr_tWSOzp3UaU-d-ZYoF0p11A"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_43b7d12c_99b6_4580_825d_1fc014dc7510"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Item 2.02. Results of Operations and Financial Condition</b><b style="color:#211d1e;font-weight:bold;">.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">On February 29, 2024, PTC Therapeutics, Inc. (the &#8220;Company&#8221;) announced its financial results for the quarter and fiscal year ended December 31, 2023. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K (this "Report") and is incorporated by reference into this Item 2.02.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-size:12pt;font-weight:normal;visibility:hidden;">&#8203;</span></p><a id="_d302d167_1063_4403_a40b_8d5d10d227b7"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-bottom:12pt;margin:0pt;">Item 7.01. Regulation FD Disclosure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;">The Company will host a conference call on February 29, 2024 at 4:30 PM eastern time, as previously announced. During this call the Company expects to review financial results for the quarter and fiscal year ended December 31, 2023, as well as other corporate highlights and updates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;">Directions on how to access the conference call are included in the press release furnished as Exhibit 99.1 hereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;">The information in this Report (including Items 2.02 and 7.01 and Exhibit 99.1) shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. All website addresses given in this Report or incorporated herein by reference are for information only and are not intended to be an active link or to incorporate any website information into this Report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_48095604_0281_4f13_826d_d5402f0cd453"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;9.01.&#160;Financial Statements and Exhibits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">(d)&#160;Exhibits</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:15%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:82.93%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;No.</b></p></td><td style="vertical-align:bottom;width:2.06%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:82.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Description</b></p></td></tr><tr><td style="vertical-align:bottom;width:15%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="tmb-20240229xex99d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">99.1</span></a></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.93%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="tmb-20240229xex99d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Press Release, dated February 29, 2024 issued by PTC Therapeutics, Inc.</span></a></p></td></tr><tr><td style="vertical-align:bottom;width:15%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">104</p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.93%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The cover page from this Current Report on Form 8-K, formatted in Inline XBRL</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_7a9a790c_ca0a_427d_8646_fdd7e62f3db0"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Signature</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:44.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:50.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">PTC Therapeutics,&#160;Inc.</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:50.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: February 29, 2024</p></td><td style="vertical-align:bottom;width:5.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:44.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Pierre Gravier</p></td></tr><tr><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:44.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Pierre Gravier</p></td></tr><tr><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:44.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tmb-20240229xex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.5.122.0--><!--Created on: 2/29/2024 08:21:37 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Exhibit 99.1</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">PTC Therapeutics Provides Corporate Update and </b><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;</font><font style="font-size:11pt;"><br></font><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Reports Fourth Quarter and Full Year 2023 Financial Results</b><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;</font><font style="font-size:11pt;"><br></font><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;"><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">&#8211; 34% year-over-year growth in 2023 total revenue &#8211;</i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;line-height:1.27;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;"><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">&#8211; Global filings of sepiapterin remain on track with first submission of the EU MAA expected in March &#8211; </i><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:center;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;text-align:center;background:#ffffff;margin:0pt 53pt 0pt 60.5pt;"><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;font-weight:normal;">&#8211; Potential NDA submission for vatiquinone for Friedreich ataxia expected in late 2024 &#8211; </i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">SOUTH PLAINFIELD, N.J., Feb. 29, 2024</b><font style="font-family:'Arial','Helvetica','sans-serif';"> &#8211; PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced a corporate update and financial results for the fourth quarter and full year ending December 31, 2023.&#160;&#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#212121;font-family:'Arial','Helvetica','sans-serif';">&#8220;We closed out 2023 with strong revenue performance in the fourth quarter,&#8221; said Matthew Klein, M.D., Chief Executive Officer, PTC Therapeutics, Inc. &#8220;We are well-positioned for a successful 2024 with several potential&#160;exciting clinical and regulatory milestones ahead. We look forward to initiating the global regulatory submissions for sepiapterin for the treatment of PKU, which we see as a potential billion-dollar opportunity, as well as to advancing our PTC518, vatiquinone, and utreloxastat programs.&quot;&#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Key Corporate Updates:</b><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">2023 total revenue of $938 million, representing 34% year-over-year growth</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">2023 revenue for the DMD franchise was $611 million</font></td></tr></table><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-left:22.5pt;margin-top:0pt;padding-left:18pt;text-indent:-18pt;"><font style="display:inline-block;font-family:'Courier New';font-size:10pt;min-width:18pt;text-indent:0pt;white-space:nowrap;">o</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">Translarna&#8482; (ataluren) net product revenue was $356 million, driven by</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;"> new patients in existing geographies and continued geographic expansion.</font></div><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-left:22.5pt;margin-top:0pt;padding-left:18pt;text-indent:-18pt;"><font style="display:inline-block;font-family:'Courier New';font-size:10pt;min-width:18pt;text-indent:0pt;white-space:nowrap;">o</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">Emflaza</font><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;vertical-align:top;">&#174;</sup><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;"> (deflazacort) net product revenue was $255 million, resulting from </font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">new patient starts and high compliance. </font></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Key Clinical and Regulatory Milestones:</b><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">PTC expects to submit an MAA to the EMA for sepiapterin for the treatment of PKU in March 2024 and expects to submit an NDA to the FDA for sepiapterin no later than the third quarter of 2024. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">PTC had a Type C meeting with the FDA in the first quarter of 2024 to discuss the vatiquinone Friedreich ataxia program. Based on discussions with the FDA, PTC has a potential path to an NDA submission in late 2024 based on the placebo-controlled results of MOVE-FA, along with data from the ongoing open-label extension study.  </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">PTC expects to submit a BLA to the FDA for Upstaza&#8482; for the treatment of AADC deficiency in March 2024.</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"> </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">PTC expects to meet with the FDA to discuss a potential NDA resubmission of Translarna in March 2024.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">PTC expects to provide an interim data update for the PIVOT-HD trial of PTC518 for Huntington&#8217;s disease patients in the second quarter of 2024. This update will include 12-month data on the initial group of subjects for which data was reported in June 2023.&#160;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">PTC expects to report topline data for the CardinALS trial of utreloxastat for ALS in the fourth quarter of 2024. </font></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Fourth Quarter and Full Year 2023 Financial Highlights:</b><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Total revenue was $307.1 million for the fourth quarter of 2023, compared to $167.4 million for the fourth quarter of 2022. Total revenue was&#160;$937.8 million for full year 2023, compared to $698.8 million for full year 2022.&#160;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Total revenue included net product revenue across the commercial portfolio of $155.1 million for the fourth quarter of 2023 and $661.2 million for full year 2023, compared to $127.5 million for the fourth quarter of 2022 and $535.2 million for full year 2022. Total revenue also included collaboration, royalty, and manufacturing revenue of $152.0 million in fourth quarter of 2023 and $276.6 million for full year 2023, compared to $39.9 million for the fourth quarter of 2022 and $163.6 million for full year 2022.&#160;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Translarna net product revenue was $75.2 million for the fourth quarter of 2023, compared to $55.8 million for the fourth quarter of 2022. Translarna net product revenue was $355.8 million for full year 2023, compared to $288.6 million for full year 2022. These results were driven by treatment of new patients in existing geographies and continued geographic expansion.&#160;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Emflaza net product revenue was $67.4 million for the fourth quarter of 2023, compared to $58.1 million for the fourth quarter of 2022. Emflaza net product revenue was $255.1 million for full year 2023, compared to $218.3 million for full year 2022. These results were driven by new patient starts and high compliance.&#160;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Roche reported Evrysdi</font><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;font-style:normal;font-weight:normal;vertical-align:top;">&#174;</sup><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"> full year 2023 sales of approximately CHF 1,419 million, resulting in full year 2023 royalty revenue of $168.9 million to PTC, as compared to $113.5 million for full year 2022. </font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Also in the fourth quarter of 2023, PTC recorded a sales milestone of $100.0 million for the achievement of $1.5 billion in worldwide annual net sales from Evrysdi. This sales milestone was recorded as collaboration revenue. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Based on U.S. GAAP (Generally Accepted Accounting Principles), GAAP R&amp;D expense was $121.4 million for the fourth quarter of 2023, compared to $188.7 million for the fourth quarter of 2022. GAAP R&amp;D expense was $666.6 million for full year 2023, compared to $651.5 million for full year 2022. The decrease in R&amp;D expense for the fourth quarter of 2023 reflects the strategic portfolio prioritization as the Company continues to focus its resources on its differentiated, high-potential R&amp;D programs. The increase in R&amp;D expense for full year 2023 is primarily due to the achievement of a $30.0 million success-based development milestone for the completion of enrollment of a Phase 3 clinical trial for sepiapterin for PKU, partially offset by the Company&#8217;s strategic portfolio prioritization.&#160;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Non-GAAP R&amp;D expense was $113.2 million for the fourth quarter of 2023, excluding $8.1 million in non-cash, stock-based compensation expense, compared to $174.7 million for the fourth quarter of 2022, excluding $14.0 million in non-cash, stock-based compensation expense. Non-GAAP R&amp;D expense was $613.6 million for full year 2023, excluding $52.9 million in non-cash, stock-based compensation expense, compared to $595.6 million for full year 2022, excluding $55.9 million in non-cash, stock-based compensation expense.&#160;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">GAAP SG&amp;A expense was $76.3 million for the fourth quarter of 2023, compared to $92.7 million for the fourth quarter of 2022. GAAP SG&amp;A expense was $332.5 million for full year 2023, compared to $326.0 million for full year 2022.</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"> </font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">The decrease in SG&amp;A expense for the fourth quarter of 2023 was primarily due to lower employee costs as a result of the reduction in workforce. The increase in SG&amp;A expense for full year 2023 reflected the Company&#8217;s continued investment to support commercial activities, including the expanding commercial portfolio, and restructuring costs from the reduction in workforce in the year ended December 31, 2023.&#160;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Non-GAAP SG&amp;A expense was $67.9 million for the fourth quarter of 2023, excluding $8.4 million in non-cash, stock-based compensation expense, compared to $79.3 million for the fourth quarter of 2022, excluding $13.4 million in non-cash, stock-based compensation expense. Non-GAAP SG&amp;A expense was $283.8 million for full year 2023, excluding $48.7 million in non-cash, stock-based </font></td></tr></table></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:auto;width:100%;"><tr style="height:15pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt -5.75pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt -5.75pt 0pt 0pt;"><font style="margin-right:0pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">compensation expense, compared to $271.5 million for full year 2022, excluding $54.5 million in non-cash, stock-based compensation expense.&#160;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">The intangible asset impairment was $217.8 million for full year 2023, which represented a non-cash charge. This was a result of the Company&#8217;s strategic portfolio prioritization and its decision to discontinue its preclinical and early research programs in its gene therapy platform, which included FA and AS, which was announced in May 2023. No intangible asset impairment was recorded in the fourth quarter of 2023. The intangible asset impairment was $33.4 million for the fourth quarter and full year 2022, which represented a non-cash charge related to a decrease in projected cash flows for Upstaza due to refinements in market assumptions.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">The change in the fair value of deferred and contingent consideration was a gain of $2.7 million for the fourth quarter of 2023, compared to a loss of $6.3 million for the fourth quarter of 2022. The change in the fair value of deferred and contingent consideration was a gain of $127.7 million for full year 2023, compared to a gain of $25.9 million for full year 2022. </font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">The change in the fair value of deferred and contingent consideration was primarily related to the fair valuation of potential future consideration to be paid to former equity holders of Agilis Biotherapeutics, Inc. (Agilis) in connection with PTC&#8217;s acquisition of Agilis, which closed in August 2018. The Company&#8217;s strategic portfolio prioritization and its decision to discontinue its preclinical and early research programs in its gene therapy platform, which included FA and AS, was announced in May 2023. As a result, PTC determined the fair value for all the contingent consideration payable related to FA and AS was $0.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">The loss on extinguishment of debt was $137.6 million for the fourth quarter of 2023 and full year 2023, compared to $0.0 million for the fourth quarter of 2022 and full year 2022. The increase was primarily due to the early termination of the Company&#8217;s Blackstone Credit Agreement, which resulted in a loss on the extinguishment of debt of $92.7 million for the period ended December 31, 2023. In addition, the Company recorded a $44.9 million loss on extinguishment of debt for the period ended December 31, 2023, relating to the A&amp;R Royalty Purchase Agreement, which represented a non-cash charge.&#160;&#160;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">The net loss was $155.8 million for the fourth quarter of 2023, compared to a net loss of $170.9 million for the fourth quarter of 2022. The net loss was $626.6 million for full year 2023, compared to a net loss of $559.0 million for full year 2022.&#160;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Cash, cash equivalents, and marketable securities was $876.7 million on December 31, 2023, compared to $410.7 million at December 31, 2022.&#160;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Shares issued and outstanding as of December 31, 2023, were 75,708,889.&#160;</font></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">PTC Updates Full Year 2024 Financial Guidance:</b></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">PTC anticipates total revenues for full year 2024 to be between $600 million and $680 million.&#160;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">PTC anticipates GAAP R&amp;D and SG&amp;A expense for full year 2024 to be between $740 million and $835 million.&#160;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">PTC anticipates Non-GAAP R&amp;D and SG&amp;A expense for full year 2024 to be between $660 million and $755 million, including expected R&amp;D expense milestone payments of up to $65 million and excluding estimated non-cash, stock-based compensation expense of $80 million.&#160;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">PTC anticipates up to $90 million of payments for full year 2024 upon achievement of potential regulatory success-based milestones from previous acquisitions, of which up to $65 million will be recorded as R&amp;D operating expense.&#160;</font></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Non-GAAP Financial Measures:</b><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">In this press release, the financial results of PTC are provided in accordance with GAAP and using certain non-GAAP financial measures. In particular, the non-GAAP R&amp;D and SG&amp;A expense financial measures exclude non-cash, stock-based compensation expense. These non-GAAP financial measures </font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:auto;width:100%;"><tr style="height:15pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt -5.75pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt -5.75pt 0pt 0pt;"><font style="margin-right:0pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">are provided as a complement to financial measures reported in GAAP because management uses these non-GAAP financial measures when assessing and identifying operational trends. In management&#39;s opinion, these non-GAAP financial measures are useful to investors and other users of PTC&#39;s financial statements by providing greater transparency into the historical and projected operating performance of PTC and the company&#39;s future outlook. Non-GAAP financial measures are not an alternative for financial measures prepared in accordance with GAAP. Quantitative reconciliations of the non-GAAP financial measures to their respective closest equivalent GAAP financial measures are included in the table below.</font><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:auto;width:100%;"><tr style="height:15pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt -5.75pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt -5.75pt 0pt 0pt;"><font style="margin-right:0pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 146.25pt 0pt 133.5pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">PTC Therapeutics, Inc.</b><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font><font style="font-family:'Arial','Helvetica','sans-serif';"><br></font><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Consolidated Statements of Operations</b><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font><font style="font-family:'Arial','Helvetica','sans-serif';"><br></font><font style="font-family:'Arial','Helvetica','sans-serif';">(In thousands, except share and per share data)&#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:justify;margin:0pt 0pt 0pt 18pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:99.87%;"><tr style="height:0.75pt;"><td style="vertical-align:middle;width:53.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:bottom;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:bottom;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:bottom;width:0.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:bottom;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:bottom;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:bottom;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:bottom;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:bottom;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:bottom;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:bottom;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:bottom;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:53.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:bottom;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:bottom;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:bottom;width:0.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:bottom;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:bottom;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:bottom;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:bottom;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:bottom;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:bottom;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:bottom;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:bottom;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:53.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="5" style="vertical-align:middle;width:22.8%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Three Months Ended December 31,&#8239;</b><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:bottom;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="5" style="vertical-align:middle;width:22.15%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Twelve Months Ended December 31,</b><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:53.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.22%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">2023</b><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:0.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.09%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">2022</b><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:bottom;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">2023</b><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.72%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">2022</b><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:53.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Revenues:&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:0.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.09%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:bottom;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:53.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Net product revenue&#160;</font></p></td><td style="vertical-align:middle;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">$&#160;</font></p></td><td style="vertical-align:middle;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;155,062&#160;</font></p></td><td style="vertical-align:middle;width:0.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">$&#160;</font></p></td><td style="vertical-align:middle;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;127,508&#160;</font></p></td><td style="vertical-align:middle;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">$&#160;</font></p></td><td style="vertical-align:middle;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;661,249&#160;</font></p></td><td style="vertical-align:middle;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">$&#160;</font></p></td><td style="vertical-align:middle;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;535,228&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:53.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Collaboration revenue&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;100,024&#160;</font></p></td><td style="vertical-align:middle;width:0.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.09%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;28&#160;</font></p></td><td style="vertical-align:middle;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;100,030&#160;</font></p></td><td style="vertical-align:middle;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;50,052&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:53.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Royalty revenue&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;50,999&#160;</font></p></td><td style="vertical-align:middle;width:0.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.09%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;39,876&#160;</font></p></td><td style="vertical-align:middle;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;168,856&#160;</font></p></td><td style="vertical-align:middle;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;113,521&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:53.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Manufacturing revenue&#160;</font></p></td><td style="vertical-align:middle;width:1.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;971&#160;</font></p></td><td style="vertical-align:middle;width:0.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:1.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:8.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;-&#160;</font></p></td><td style="vertical-align:middle;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:1.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:8.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;7,687&#160;</font></p></td><td style="vertical-align:middle;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;-&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:53.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Total revenues&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;307,056&#160;</font></p></td><td style="vertical-align:middle;width:0.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;167,412&#160;</font></p></td><td style="vertical-align:middle;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;937,822&#160;</font></p></td><td style="vertical-align:middle;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;698,801&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:53.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Operating expenses:&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:0.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.09%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:53.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Cost of product sales, excluding amortization of acquired intangible assets&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;29,118&#160;</font></p></td><td style="vertical-align:middle;width:0.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.09%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;10,893&#160;</font></p></td><td style="vertical-align:middle;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;65,486&#160;</font></p></td><td style="vertical-align:middle;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;44,678&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:53.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Amortization of acquired intangible asset&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;77,174&#160;</font></p></td><td style="vertical-align:middle;width:0.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.09%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;35,764&#160;</font></p></td><td style="vertical-align:middle;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;222,635&#160;</font></p></td><td style="vertical-align:middle;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;116,554&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:53.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Research and development (1)&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;121,353&#160;</font></p></td><td style="vertical-align:middle;width:0.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.09%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;188,694&#160;</font></p></td><td style="vertical-align:middle;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;666,563&#160;</font></p></td><td style="vertical-align:middle;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;651,496&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:53.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Selling, general and administrative (2)&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;76,291&#160;</font></p></td><td style="vertical-align:middle;width:0.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.09%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;92,718&#160;</font></p></td><td style="vertical-align:middle;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;332,540&#160;</font></p></td><td style="vertical-align:middle;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;325,998&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:53.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Change in the fair value of deferred and contingent consideration&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;(2,700)&#160;</font></p></td><td style="vertical-align:middle;width:0.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.09%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;6,300&#160;</font></p></td><td style="vertical-align:middle;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;(127,700)&#160;</font></p></td><td style="vertical-align:middle;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;(25,900)&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:53.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Intangible asset impairment&#160;&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;-&#160;</font></p></td><td style="vertical-align:middle;width:0.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;33,384&#160;</font></p></td><td style="vertical-align:middle;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;217,800&#160;</font></p></td><td style="vertical-align:middle;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;33,384&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:53.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Total operating expenses&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;301,236&#160;</font></p></td><td style="vertical-align:middle;width:0.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;367,753&#160;</font></p></td><td style="vertical-align:middle;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;1,377,324&#160;</font></p></td><td style="vertical-align:middle;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;1,146,210&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:53.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Income (loss) from operations&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;5,820&#160;</font></p></td><td style="vertical-align:middle;width:0.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.09%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;(200,341)&#160;</font></p></td><td style="vertical-align:middle;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;(439,502)&#160;</font></p></td><td style="vertical-align:middle;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;(447,409)&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:53.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Interest expense, net&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;(44,274)&#160;</font></p></td><td style="vertical-align:middle;width:0.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.09%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;(24,500)&#160;</font></p></td><td style="vertical-align:middle;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;(129,180)&#160;</font></p></td><td style="vertical-align:middle;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;(90,871)&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:53.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Other income (expense), net&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;18,961&#160;</font></p></td><td style="vertical-align:middle;width:0.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.09%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;35,147&#160;</font></p></td><td style="vertical-align:middle;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;10,130&#160;</font></p></td><td style="vertical-align:middle;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;(49,207)&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:53.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Loss on extinguishment of debt&#160;</font></p></td><td style="vertical-align:middle;width:1.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;(137,558)&#160;</font></p></td><td style="vertical-align:middle;width:0.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:1.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:8.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;-&#160;</font></p></td><td style="vertical-align:middle;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;(137,558)&#160;</font></p></td><td style="vertical-align:middle;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:1.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;-&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:53.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Loss before income tax benefit&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;(157,051)&#160;</font></p></td><td style="vertical-align:middle;width:0.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.09%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;(189,694)&#160;</font></p></td><td style="vertical-align:middle;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;(696,110)&#160;</font></p></td><td style="vertical-align:middle;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;(587,487)&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:53.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Income tax benefit&#160;&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;1,259&#160;</font></p></td><td style="vertical-align:middle;width:0.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;18,805&#160;</font></p></td><td style="vertical-align:middle;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;69,506&#160;</font></p></td><td style="vertical-align:middle;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;28,470&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:53.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Net loss attributable to common stockholders&#160;</font></p></td><td style="vertical-align:middle;width:1.43%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">$&#160;</font></p></td><td style="vertical-align:middle;width:10.79%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;(155,792)&#160;</font></p></td><td style="vertical-align:middle;width:0.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:1.43%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">$&#160;</font></p></td><td style="vertical-align:middle;width:8.66%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;(170,889)&#160;</font></p></td><td style="vertical-align:middle;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:1.47%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">$&#160;</font></p></td><td style="vertical-align:middle;width:8.52%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;(626,604)&#160;</font></p></td><td style="vertical-align:middle;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:1.43%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">$&#160;</font></p></td><td style="vertical-align:middle;width:9.29%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;(559,017)&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:53.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:0.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.09%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:53.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Weighted-average shares outstanding:&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:0.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.09%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:53.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Basic and diluted (in shares)&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.22%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;75,490,569&#160;</font></p></td><td style="vertical-align:middle;width:0.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.09%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;72,656,790&#160;</font></p></td><td style="vertical-align:middle;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;74,838,392&#160;</font></p></td><td style="vertical-align:middle;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.72%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;71,728,634&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:53.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Net loss per share&#8212;basic and diluted (in dollars per share)&#160;</font></p></td><td style="vertical-align:middle;width:1.43%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">$&#160;</font></p></td><td style="vertical-align:middle;width:10.79%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;(2.06)&#160;</font></p></td><td style="vertical-align:middle;width:0.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:1.43%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">$&#160;</font></p></td><td style="vertical-align:middle;width:8.66%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;(2.35)&#160;</font></p></td><td style="vertical-align:middle;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:1.47%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">$&#160;</font></p></td><td style="vertical-align:middle;width:8.52%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;(8.37)&#160;</font></p></td><td style="vertical-align:middle;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:1.43%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">$&#160;</font></p></td><td style="vertical-align:middle;width:9.29%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;(7.79)&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:53.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:0.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.09%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:53.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">(1) Research and development reconciliation</b><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:0.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.09%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:53.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">GAAP research and development&#160;</font></p></td><td style="vertical-align:middle;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">$&#160;</font></p></td><td style="vertical-align:middle;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;121,353&#160;</font></p></td><td style="vertical-align:middle;width:0.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">$&#160;</font></p></td><td style="vertical-align:middle;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;188,694&#160;</font></p></td><td style="vertical-align:middle;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">$&#160;</font></p></td><td style="vertical-align:middle;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;666,563&#160;</font></p></td><td style="vertical-align:middle;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">$&#160;</font></p></td><td style="vertical-align:middle;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;651,496&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:53.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Less: share-based compensation expense&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;8,113&#160;</font></p></td><td style="vertical-align:middle;width:0.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;13,973&#160;</font></p></td><td style="vertical-align:middle;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;52,941&#160;</font></p></td><td style="vertical-align:middle;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;55,869&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:53.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Non-GAAP research and development</b><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:1.43%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">$&#160;</font></p></td><td style="vertical-align:middle;width:10.79%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;113,240&#160;</font></p></td><td style="vertical-align:middle;width:0.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:1.43%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">$&#160;</font></p></td><td style="vertical-align:middle;width:8.66%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;174,721&#160;</font></p></td><td style="vertical-align:middle;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:1.47%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">$&#160;</font></p></td><td style="vertical-align:middle;width:8.52%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;613,622&#160;</font></p></td><td style="vertical-align:middle;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:1.43%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">$&#160;</font></p></td><td style="vertical-align:middle;width:9.29%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;595,627&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:53.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:0.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.09%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:53.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">(2) Selling, general and administrative reconciliation</b><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:0.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.09%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:53.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">GAAP selling, general and administrative&#160;</font></p></td><td style="vertical-align:middle;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">$&#160;</font></p></td><td style="vertical-align:middle;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;76,291&#160;</font></p></td><td style="vertical-align:middle;width:0.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">$&#160;</font></p></td><td style="vertical-align:middle;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;92,718&#160;</font></p></td><td style="vertical-align:middle;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">$&#160;</font></p></td><td style="vertical-align:middle;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;332,540&#160;</font></p></td><td style="vertical-align:middle;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">$&#160;</font></p></td><td style="vertical-align:middle;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;325,998&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:53.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Less: share-based compensation expense&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;8,395&#160;</font></p></td><td style="vertical-align:middle;width:0.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;13,370&#160;</font></p></td><td style="vertical-align:middle;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;48,695&#160;</font></p></td><td style="vertical-align:middle;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;54,464&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:53.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Non-GAAP selling, general and administrative&#160;</b><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:1.43%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">$&#160;</font></p></td><td style="vertical-align:middle;width:10.79%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;67,896&#160;</font></p></td><td style="vertical-align:middle;width:0.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:1.43%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">$&#160;</font></p></td><td style="vertical-align:middle;width:8.66%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;79,348&#160;</font></p></td><td style="vertical-align:middle;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:1.47%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">$&#160;</font></p></td><td style="vertical-align:middle;width:8.52%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;283,845&#160;</font></p></td><td style="vertical-align:middle;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:1.43%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">$&#160;</font></p></td><td style="vertical-align:middle;width:9.29%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;271,534&#160;</font></p></td></tr></table></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:auto;width:100%;"><tr style="height:15pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt -5.75pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt -5.75pt 0pt 0pt;"><font style="margin-right:0pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:99.87%;"><tr style="height:15pt;"><td style="vertical-align:middle;width:53.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:0.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.09%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:bottom;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Segoe UI';font-size:9pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:center;margin:0pt 52.5pt 0pt 60pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;">&#160;</b><font style="font-family:'Times New Roman','Times','serif';">&#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 146.25pt 0pt 133.5pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">PTC Therapeutics, Inc.</b><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font><font style="font-family:'Arial','Helvetica','sans-serif';"><br></font><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Summary Consolidated Balance Sheets</b><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font><font style="font-family:'Arial','Helvetica','sans-serif';"><br></font><font style="font-family:'Arial','Helvetica','sans-serif';">(in thousands, except share data)&#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:0.75pt;"><td style="vertical-align:middle;width:62.64%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:7.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:7.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td></tr><tr style="height:22.5pt;"><td style="vertical-align:middle;width:62.64%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:17.08%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">December 31, 2023</b><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:16.93%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">December 31, 2022</b><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td></tr><tr style="height:12.75pt;"><td style="vertical-align:middle;width:62.64%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Cash, cash equivalents and marketable securities&#160;</font></p></td><td style="vertical-align:middle;width:7.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">$&#160;</font></p></td><td style="vertical-align:middle;width:9.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;876,739&#160;</font></p></td><td style="vertical-align:middle;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:7.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">$&#160;</font></p></td><td style="vertical-align:middle;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;410,705&#160;</font></p></td></tr><tr style="height:22.5pt;"><td style="vertical-align:middle;width:62.64%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Total Assets</b><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:7.31%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">$</b><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:9.76%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;1,895,698</b><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:7.31%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">$</b><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:9.61%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;1,705,619</b><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td></tr><tr style="height:12.75pt;"><td style="vertical-align:middle;width:62.64%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:7.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:7.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td></tr><tr style="height:12.75pt;"><td style="vertical-align:middle;width:62.64%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Total debt&#160;</font></p></td><td style="vertical-align:middle;width:7.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">$&#160;</font></p></td><td style="vertical-align:middle;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;284,213&#160;</font></p></td><td style="vertical-align:middle;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:7.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">$&#160;</font></p></td><td style="vertical-align:middle;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;571,722&#160;</font></p></td></tr><tr style="height:12.75pt;"><td style="vertical-align:middle;width:62.64%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Total deferred revenue&#160;</font></p></td><td style="vertical-align:bottom;width:7.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;801&#160;</font></p></td><td style="vertical-align:middle;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:bottom;width:7.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;1,351&#160;</font></p></td></tr><tr style="height:22.5pt;"><td style="vertical-align:middle;width:62.64%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Total liability for sale of future royalties&#160;</font></p></td><td style="vertical-align:middle;width:7.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:9.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;1,814,097&#160;</font></p></td><td style="vertical-align:middle;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:7.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;757,886&#160;</font></p></td></tr><tr style="height:21.75pt;"><td style="vertical-align:middle;width:62.64%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Total liabilities</b><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:7.31%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">$</b><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:9.76%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;2,714,253</b><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:7.31%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">$</b><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:9.61%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;2,052,705</b><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td></tr><tr style="height:12.75pt;"><td style="vertical-align:middle;width:62.64%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:7.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:7.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td></tr><tr style="height:33.75pt;"><td style="vertical-align:middle;width:62.64%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Total stockholders&#39; deficit (75,708,889 and 73,104,692 common shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively)&#160;</font></p></td><td style="vertical-align:middle;width:7.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">$&#160;</font></p></td><td style="vertical-align:middle;width:9.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;(818,555)&#160;</font></p></td><td style="vertical-align:middle;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:7.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">$&#160;</font></p></td><td style="vertical-align:middle;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;(347,086)&#160;</font></p></td></tr><tr style="height:22.5pt;"><td style="vertical-align:middle;width:62.64%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Total liabilities and stockholders&#39; deficit</b><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:7.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">$</b><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;1,895,698</b><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:7.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">$</b><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;1,705,619</b><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:center;background:#ffffff;margin:0pt 0pt 0pt 6pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">PTC Therapeutics, Inc.</b><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font><font style="font-family:'Arial','Helvetica','sans-serif';"><br></font><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Reconciliation of GAAP Milestone Payments Full Year 2024</b><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:center;background:#ffffff;margin:0pt 0pt 0pt 6pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">(in millions)&#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:99.83%;"><tr style="height:0.75pt;"><td style="vertical-align:middle;width:74.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:top;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:top;width:23.59%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:74.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:25.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">PTC Therapeutics, Inc.</b><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:74.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:top;width:25.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Reconciliation of GAAP&#160;</b><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:74.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:top;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:top;width:23.59%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Milestone Payments&#160;</b><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:74.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:25.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Full Year 2024</b><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:74.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:25.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">(in millions)&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:74.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:25.36%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:74.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Projected GAAP R&amp;D Expense Related Milestone Payments&#160;</font></p></td><td style="vertical-align:middle;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">$&#160;</font></p></td><td style="vertical-align:middle;width:23.59%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;65&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:74.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Projected GAAP Contingent Consideration Payable Related Milestone Payments&#160;</font></p></td><td style="vertical-align:middle;width:1.76%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:23.59%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;25&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:74.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Total Projected GAAP Milestone Payments&#160;</font></p></td><td style="vertical-align:middle;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">$</b><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:23.59%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;90</b><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt 52.5pt 0pt 168pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">PTC Therapeutics, Inc.&#160;</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 52.5pt 0pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Reconciliation of GAAP to Non-GAAP Projected Full Year 2024 R&amp;D and SG&amp;A Expense</b><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font><font style="font-family:'Arial','Helvetica','sans-serif';"><br></font><font style="font-family:'Arial','Helvetica','sans-serif';">(In millions)&#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 52.5pt 0pt 60pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:99.83%;"><tr style="height:0.75pt;"><td style="vertical-align:middle;width:53.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:53.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:18.78%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Low End of Range</b><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:18.78%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">High End of Range</b><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:53.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Projected GAAP R&amp;D and SG&amp;A Expense&#160;</font></p></td><td style="vertical-align:middle;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">$&#160;</font></p></td><td style="vertical-align:middle;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;740&#160;</font></p></td><td style="vertical-align:middle;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">$&#160;</font></p></td><td style="vertical-align:middle;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;835&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:53.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Less: projected non-cash, stock-based compensation expense&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:18.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;80&#160;</font></p></td><td style="vertical-align:middle;width:8.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;width:18.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;80&#160;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:53.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Projected non-GAAP R&amp;D and SG&amp;A expense&#160;</b><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:8.98%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">$&#160;</font></p></td><td style="vertical-align:middle;width:9.79%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;660&#160;</font></p></td><td style="vertical-align:middle;width:8.98%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:middle;width:8.98%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">$&#160;</font></p></td><td style="vertical-align:middle;width:9.79%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;755&#160;</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;">&#160;</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:auto;width:100%;"><tr style="height:15pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt -5.75pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt -5.75pt 0pt 0pt;"><font style="margin-right:0pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Acronyms:</b><font style="font-size:12pt;"><br></font><font style="font-family:'Arial','Helvetica','sans-serif';">AS: </font><font style="font-family:'Arial','Helvetica','sans-serif';">Angelman Syndrome</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">BLA:&#160;Biologics License Application</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">CHF: Confoederatio Helvetica Francs (Swiss francs)</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">DMD: Duchenne Muscular Dystrophy</font><font style="font-size:12pt;"><br></font><font style="font-family:'Arial','Helvetica','sans-serif';">FA: Friedreich Ataxia</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">FDA: U.S. Food and Drug Administration</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">GAAP: Generally Accepted Accounting Principles</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">HD: Huntington&#8217;s Disease</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">NDA: New Drug Application</font><font style="font-size:12pt;"><br></font><font style="font-family:'Arial','Helvetica','sans-serif';">PKU: Phenylketonuria</font><font style="font-size:12pt;"><br></font><font style="font-family:'Arial','Helvetica','sans-serif';">R&amp;D: Research and Development</font><font style="font-size:12pt;"><br></font><font style="font-family:'Arial','Helvetica','sans-serif';">SG&amp;A: Selling, General and Administrative</font><font style="font-size:12pt;"><br></font><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Today&#39;s Conference Call and Webcast Reminder: </b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">To access the call by phone, please </font><font style="font-family:'Arial','Helvetica','sans-serif';">click here</font><font style="font-family:'Arial','Helvetica','sans-serif';"> to register and you will be provided with dial-in details. To avoid delays, we recommend participants dial in to the conference call 15 minutes prior to the start of the call. The webcast conference call can be accessed on the Investor section of the PTC website at </font><font style="font-family:'Arial','Helvetica','sans-serif';">https://ir.ptcbio.com/events-presentations</font><font style="font-family:'Arial','Helvetica','sans-serif';">. A replay of the call will be available approximately two hours after completion of the call and will be archived on the company&#39;s website for 30 days following the call.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">About PTC Therapeutics, Inc.</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">PTC is a global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. PTC&#39;s ability to globally commercialize products is the foundation that drives investment in a robust and diversified pipeline of transformative medicines and our mission to provide access to best-in-class treatments for patients who have an unmet medical need. The company&#39;s strategy is to leverage its strong scientific expertise and global commercial infrastructure to maximize value for its patients and other stakeholders. To learn more about PTC, please visit us at </font><font style="font-family:'Arial','Helvetica','sans-serif';">www.ptcbio.com</font><font style="font-family:'Arial','Helvetica','sans-serif';"> and follow us on Facebook, on Twitter at @PTCBio, and on LinkedIn.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">For More Information:</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Investors:</b><font style="font-size:11pt;"><br></font><font style="font-family:'Arial','Helvetica','sans-serif';">Kylie O&#39;Keefe</font><font style="font-size:11pt;"><br></font><font style="font-family:'Arial','Helvetica','sans-serif';">+1 (908) 300-0691</font><font style="font-size:11pt;"><br></font><font style="font-family:'Arial','Helvetica','sans-serif';">kokeefe@ptcbio.com</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Media:</b><font style="font-size:11pt;"><br></font><font style="font-family:'Arial','Helvetica','sans-serif';">Jeanine Clemente</font><font style="font-size:11pt;"><br></font><font style="font-family:'Arial','Helvetica','sans-serif';">+1 (908) 912-9406</font><font style="font-size:11pt;"><br></font><font style="font-family:'Arial','Helvetica','sans-serif';">jclemente@ptcbio.com</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Forward-Looking Statements:</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this release, other than statements of historic fact, are forward-looking statements, including the information provided under the heading &quot;PTC Updates Full Year 2024 Revenue Guidance&quot;, including with respect to (i) 2024 total revenue guidance, (ii) 2024 GAAP and non-GAAP R&amp;D and SG&amp;A expense guidance and (iii) 2024 acquisition related milestone </font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:auto;width:100%;"><tr style="height:15pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt -5.75pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt -5.75pt 0pt 0pt;"><font style="margin-right:0pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">payment guidance, and statements regarding: the future expectations, plans and prospects for PTC, including with respect to the expected timing of clinical trials and studies, availability of data, regulatory submissions and responses, commercialization and other matters with respect to its products and product candidates; PTC&#39;s strategy, future operations, future financial position, future revenues, projected costs; the extent, timing and financial aspects of our strategic pipeline prioritization and reductions in workforce; and the objectives of management. Other forward-looking statements may be identified by the words, &quot;guidance&quot;, &quot;plan,&quot; &quot;anticipate,&quot; &quot;believe,&quot; &quot;estimate,&quot; &quot;expect,&quot; &quot;intend,&quot; &quot;may,&quot; &quot;target,&quot; &quot;potential,&quot; &quot;will,&quot; &quot;would,&quot; &quot;could,&quot; &quot;should,&quot; &quot;continue,&quot; and similar expressions.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">PTC&#39;s actual results, performance or achievements could differ materially from those expressed or implied by forward-looking statements it makes as a result of a variety of risks and uncertainties, including those related to: the outcome of pricing, coverage and reimbursement negotiations with third party payors for PTC&#39;s products or product candidates that PTC commercializes or may commercialize in the future; PTC&#39;s ability to maintain its marketing authorization of Translarna for the treatment of nmDMD in Brazil, Russia, the European Economic Area (EEA) and other regions, including whether the European Commission adopts the negative opinion from the Committee for Medicinal Products for Human Use (CHMP) for the conditional marketing authorization for Translarna in the EEA; PTC&#39;s ability to use the results of Study 041, a randomized, 18-month, placebo-controlled clinical trial of Translarna for the treatment of nmDMD followed by an 18-month open-label extension, and from its international drug registry study to support a marketing approval for Translarna for the treatment of nmDMD in the United States; whether investigators agree with PTC&#39;s interpretation of the results of clinical trials and the totality of clinical data from our trials in Translarna; expectations with respect to Upstaza, including any regulatory submissions and potential approvals, commercialization, manufacturing capabilities, the potential achievement of development, regulatory and sales milestones and contingent payments that PTC may be obligated to make; expectations with respect to the commercialization of Evrysdi under our SMA collaboration; expectations with respect to the commercialization of Tegsedi and Waylivra; the timing of and actual expenses incurred in connection with the discontinuation of PTC&#39;s preclinical and early research programs in gene therapy and reductions in workforce, which may be in different periods and may be materially higher than estimated; the savings that may result from the discontinuation of PTC&#39;s strategic pipeline prioritization and reductions in workforce, which may be materially less than expected; significant business effects, including the effects of industry, market, economic, political or regulatory conditions; changes in tax and other laws, regulations, rates and policies; the eligible patient base and commercial potential of PTC&#39;s products and product candidates; PTC&#39;s scientific approach and general development progress; the potential financial impact and benefits of PTC&#39;s leased biologics manufacturing facility; PTC&#39;s ability to satisfy its obligations under the terms of its lease agreements, including for its leased biologics manufacturing facility; the sufficiency of PTC&#39;s cash resources and its ability to obtain adequate financing in the future for its foreseeable and unforeseeable operating expenses and capital expenditures; and the factors discussed in the &quot;Risk Factors&quot; section of PTC&#39;s most recent Annual Report on Form 10-K, as well as any updates to these risk factors filed from time to time in PTC&#39;s other filings with the SEC. You are urged to carefully consider all such factors.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that any product will receive or maintain regulatory approval in any territory, or prove to be commercially successful, including Translarna, Emflaza, Upstaza, Evrysdi, Tegsedi or Waylivra.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">The forward-looking statements contained herein represent PTC&#39;s views only as of the date of this press release and PTC does not undertake or plan to update or revise any such forward-looking statements to reflect actual results or changes in plans, prospects, assumptions, estimates or projections, or other circumstances occurring after the date of this press release except as required by law.</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:auto;width:100%;"><tr style="height:15pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt -5.75pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt -5.75pt 0pt 0pt;"><font style="margin-right:0pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>tmb-20240229.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.5.0.8 -->
<!--Based on XBRL 2.1-->
<!--Created on: 2/29/2024 8:21:43 PM-->
<!--Modified on: 2/29/2024 8:21:43 PM-->
<xsd:schema targetNamespace="http://www.ptcbio.com/20240229" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:srt-roles="http://fasb.org/srt-roles/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ptct="http://www.ptcbio.com/20240229" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:cef="http://xbrl.sec.gov/cef/2023" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="tmb-20240229_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="tmb-20240229_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>tmb-20240229_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.5.0.8 -->
<!--Based on XBRL 2.1-->
<!--Created on: 2/29/2024 8:21:43 PM-->
<!--Modified on: 2/29/2024 8:21:43 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink">
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Written Communications</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Soliciting Material</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Issuer Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>tmb-20240229_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.5.0.8 -->
<!--Based on XBRL 2.1-->
<!--Created on: 2/29/2024 8:21:43 PM-->
<!--Modified on: 2/29/2024 8:21:43 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="tmb-20240229.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638448349035615226" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentType_638448349035615226" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638448349035615226" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_638448349035615226" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638448349035615226" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityFileNumber_638448349035615226" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638448349035615226" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityRegistrantName_638448349035615226" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638448349035615226" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_638448349035615226" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638448349035615226" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_638448349035615226" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638448349035615226" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_638448349035615226" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638448349035615226" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_638448349035615226" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638448349035625238" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_638448349035625238" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638448349035625238" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_638448349035625238" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638448349035625238" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_CityAreaCode_638448349035625238" order="11" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638448349035625238" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_LocalPhoneNumber_638448349035625238" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications_638448349035625238" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_WrittenCommunications_638448349035625238" order="13" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial_638448349035625238" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_SolicitingMaterial_638448349035625238" order="14" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer_638448349035625238" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_PreCommencementTenderOffer_638448349035625238" order="15" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer_638448349035625238" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer_638448349035625238" order="16" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638448349035625238" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_Security12bTitle_638448349035625238" order="17" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638448349035635256" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_TradingSymbol_638448349035635256" order="18" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638448349035635256" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_SecurityExchangeName_638448349035635256" order="19" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638448349035635256" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_638448349035635256" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638448349035635256" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCentralIndexKey_638448349035635256" order="21" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638448349035635256" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AmendmentFlag_638448349035635256" order="22" use="optional" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139653111868208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Feb. 29, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Feb. 29,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-35969<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PTC THERAPEUTICS, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">04-3416587<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">100 Corporate Court<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">South Plainfield<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07080<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">908<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">222-7000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PTCT<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001070081<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>8
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MLL1(:L,/<'-^BQB9O48;*M;LY *I1>AQLKB?_(XQ'>T.SG+Z6<;4VD;I'2A
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M;%!+ 0(4 Q0    ( .^!75B=QKOT[P   "L"   1              "  :\
M  !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( .^!75B97)PC$ 8  )PG
M   3              "  <T!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#
M%     @ [X%=6 <.5$96!   NA   !@              ("!#@@  'AL+W=O
M<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( .^!75B?H!OPL0(  .(,
M   -              "  9H,  !X;"]S='EL97,N>&UL4$L! A0#%     @
M[X%=6)>*NQS     $P(   L              ( !=@\  %]R96QS+RYR96QS
M4$L! A0#%     @ [X%=6!PX9>H_ 0  / (   \              ( !7Q
M 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( .^!75@D'INBK0   /@!   :
M              "  <L1  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+
M 0(4 Q0    ( .^!75AED'F2&0$  ,\#   3              "  ; 2  !;
H0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D /@(  /H3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="tmb-20240229x8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>tmb-20240229.xsd</File>
    <File>tmb-20240229_lab.xml</File>
    <File>tmb-20240229_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" original="tmb-20240229x8k.htm">tmb-20240229x8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "tmb-20240229x8k.htm": {
   "nsprefix": "ptct",
   "nsuri": "http://www.ptcbio.com/20240229",
   "dts": {
    "schema": {
     "local": [
      "tmb-20240229.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "tmb-20240229_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "tmb-20240229_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "tmb-20240229x8k.htm"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 22
   },
   "report": {
    "R1": {
     "role": "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation",
     "longName": "00090 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "Duration_2_29_2024_To_2_29_2024_g9hADND3XUK0dRK0JVWoBA",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20240229x8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_2_29_2024_To_2_29_2024_g9hADND3XUK0dRK0JVWoBA",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20240229x8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document and Entity Information [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001558370-24-002189-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-24-002189-xbrl.zip
M4$L#!!0    ( .^!75B,_],M= ,  $@,   0    =&UB+3(P,C0P,C(Y+GAS
M9+5676_:,!1]G[3_X.4]'X1V*@A:K>LF58)MZCJI;Y-Q#%A+[,QV"OWWNS9Q
M("$)=-J>"#['YQ[?ZWN3R<TV2]$SE8H)/O4&0>0ARHE(&%]-O4+Y6!'&O)OK
MMV\F[WS_Z?9AAA)!BHQRC8BD6-,$;9A>HT>1YYBC.962I2FZE2Q9480&47 9
M1,$5\OU2XQ8KV",XLF)Q,*B0CZ6>X&,4A_$HC*/X EV-X\'X8HB^S2OB'/PM
MV4GF5B5C1=8TPTACN:+Z"\ZHRC&A4V^M=3X.P\UF$^2:+)@(B,BL3!3'(P]A
MK25;%)I^%C*[HTM<I!H2PG\7.+6Q(4\I-6FH$0Y@2"Q78_!0"[89!D*N(% T
M")_FL^_6GB,GE%7D[4*F@:(D6(GG$ #C;>B(4)@5QGE%7F*UL+HE4",KJ7W]
MDE-U3*^@IKH4:1O?(36ZI,O:$:WS\I#O0T"K7 "0Z/H)2]YEN ,=E112PCU\
M:4^'0VLVMFFGBV'X-&/\EV-RS(AJ5[;04?8ZLE%!M0U$%%S++N<[L)YN+3N=
MCT) #ZRTFJBII7#0GD08> $=Z.AT2];M5@W22'!3NKS,@]%H%%JT<LI(NR@
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MW$ZG!;F-TX+:SNL9711T2<JIN;6JF;F)SSI><ZE\CO]<4A"9;NGX5K"O[/
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MQK^^=MQ'$L5CC_WKQ9"&?=>OQ#SHF+4@OH8WK^#KF6=^5$:N$P\Z>JWVC^N
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M%-2M;;,H N:3>E..'08= M<&F6:6B\5^V/ R3,H&&@-)/,&W(>LGH'=Y."9
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M3+,VRFH;FX*LQ2,P36,5;)I+JQC-&:]I!F4]Z11NS,#K^L\'<D=G4>4<F9^
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M_P]02P$"% ,4    " #O@5U8C/_3+70#  !(#   $               @ $
M    =&UB+3(P,C0P,C(Y+GAS9%!+ 0(4 Q0    ( .^!75C@Q'2*:@4  .X[
M   4              "  :(#  !T;6(M,C R-# R,CE?;&%B+GAM;%!+ 0(4
M Q0    ( .^!75C?3?O/<00  .XE   4              "  3X)  !T;6(M
M,C R-# R,CE?<')E+GAM;%!+ 0(4 Q0    ( .^!75A#E)B&.18  *^N   3
M              "  >$-  !T;6(M,C R-# R,CEX.&LN:'1M4$L! A0#%
M  @ [X%=6#KO#?NO-0  .S<# !<              ( !2R0  '1M8BTR,#(T
E,#(R.7AE>#DY9#$N:'1M4$L%!@     %  4 2 $  "]:      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>tmb-20240229x8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="tmb-20240229.xsd" xlink:type="simple"/>
    <context id="Duration_2_29_2024_To_2_29_2024_g9hADND3XUK0dRK0JVWoBA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
        </entity>
        <period>
            <startDate>2024-02-29</startDate>
            <endDate>2024-02-29</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="Duration_2_29_2024_To_2_29_2024_g9hADND3XUK0dRK0JVWoBA"
      id="Tc_cIFpiC3XdUWBvdZnJ-vSNQ_2_1">0001070081</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="Duration_2_29_2024_To_2_29_2024_g9hADND3XUK0dRK0JVWoBA"
      id="Tc_a1EH3V3txkulBPp7HTVVQQ_3_1">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="Duration_2_29_2024_To_2_29_2024_g9hADND3XUK0dRK0JVWoBA"
      id="Narr_PR4ssrHA8kSo6vj8KUfkQQ">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_2_29_2024_To_2_29_2024_g9hADND3XUK0dRK0JVWoBA"
      id="Narr_7qk3w9mIQ06n6k0heq9CBA">2024-02-29</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="Duration_2_29_2024_To_2_29_2024_g9hADND3XUK0dRK0JVWoBA"
      id="Narr_SH9MVZt7Fkib9NX50J_ceg">PTC THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_2_29_2024_To_2_29_2024_g9hADND3XUK0dRK0JVWoBA"
      id="Tc_txef5zQOVEKDFL3URT-GZw_1_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="Duration_2_29_2024_To_2_29_2024_g9hADND3XUK0dRK0JVWoBA"
      id="Tc_Ll3fVuA9PkehTmBdDWRX4Q_1_2">001-35969</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_2_29_2024_To_2_29_2024_g9hADND3XUK0dRK0JVWoBA"
      id="Tc_zvGLVyO7PUiVlqD_HaSPKw_1_4">04-3416587</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_2_29_2024_To_2_29_2024_g9hADND3XUK0dRK0JVWoBA"
      id="Tc_XBUCC2Rsn0CvyetDFZd8-Q_1_0">100 Corporate Court</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_2_29_2024_To_2_29_2024_g9hADND3XUK0dRK0JVWoBA"
      id="Narr_P9kt5sUGHUSfZO5L7oMVJg">South Plainfield</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_2_29_2024_To_2_29_2024_g9hADND3XUK0dRK0JVWoBA"
      id="Narr_7wIQvYTIMECUTbHTw5aKeg">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_2_29_2024_To_2_29_2024_g9hADND3XUK0dRK0JVWoBA"
      id="Tc_HN8l5sA2sE6Ef31NTQ7Bww_2_2">07080</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_2_29_2024_To_2_29_2024_g9hADND3XUK0dRK0JVWoBA"
      id="Narr_2_FLiF99GE-V6F9fs5NnSA">908</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_2_29_2024_To_2_29_2024_g9hADND3XUK0dRK0JVWoBA"
      id="Narr_d5M2yavbJU2nHicoAuigrw">222-7000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="Duration_2_29_2024_To_2_29_2024_g9hADND3XUK0dRK0JVWoBA"
      id="Narr_n1jrmQcbtkujW2hTC6t_Ng">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="Duration_2_29_2024_To_2_29_2024_g9hADND3XUK0dRK0JVWoBA"
      id="Narr_WevhHgZStk6AsHMTQO0wsQ">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="Duration_2_29_2024_To_2_29_2024_g9hADND3XUK0dRK0JVWoBA"
      id="Narr_a9jxHFEf9ESE79h9zSnYJw">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="Duration_2_29_2024_To_2_29_2024_g9hADND3XUK0dRK0JVWoBA"
      id="Narr_JAmeC3OyU0ipisgtoPR_dQ">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="Duration_2_29_2024_To_2_29_2024_g9hADND3XUK0dRK0JVWoBA"
      id="Tc_Mu3NUdZGdk6ApAm2l-gaWQ_2_0">Common Stock, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_2_29_2024_To_2_29_2024_g9hADND3XUK0dRK0JVWoBA"
      id="Tc_jgEwRN5KMkGCJXn3WT6QYw_2_2">PTCT</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_2_29_2024_To_2_29_2024_g9hADND3XUK0dRK0JVWoBA"
      id="Tc_M4HEJyC9aEuATAHy5Os8pw_2_4">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_2_29_2024_To_2_29_2024_g9hADND3XUK0dRK0JVWoBA"
      id="Narr_tWSOzp3UaU-d-ZYoF0p11A">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
